[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Agenus Inc (AGEN)

Agenus Inc (AGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 129,507
  • Shares Outstanding, K 41,642
  • Annual Sales, $ 114,200 K
  • Annual Income, $ 120 K
  • EBIT $ 8 M
  • EBITDA $ 18 M
  • 60-Month Beta 1.60
  • Price/Sales 1.15
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 188.72% (+65.47%)
  • Historical Volatility 94.47%
  • IV Percentile 89%
  • IV Rank 23.77%
  • IV High 524.17% on 02/06/26
  • IV Low 84.12% on 08/04/25
  • Expected Move (DTE 25) 0.68 (21.86%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 165
  • Volume Avg (30-Day) 237
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 5,404
  • Open Int (30-Day) 9,232
  • Expected Range 2.43 to 3.79

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.06
  • Number of Estimates 1
  • High Estimate $0.06
  • Low Estimate $0.06
  • Prior Year $-1.00
  • Growth Rate Est. (year over year) +106.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.02 +2.98%
on 05/19/26
4.57 -31.95%
on 04/27/26
-0.83 (-21.07%)
since 04/22/26
3-Month
2.90 +7.24%
on 03/09/26
5.08 -38.78%
on 04/15/26
+0.05 (+1.63%)
since 02/20/26
52-Week
2.71 +14.76%
on 02/05/26
7.34 -57.63%
on 07/11/25
-0.68 (-17.94%)
since 05/22/25

Most Recent Stories

More News
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

First presentation of BOT+BAL melanoma data in heavily pretreated patients whose disease had resisted prior checkpoint therapy and who had poor-risk disease features In the overall BOT+BAL...

AGEN : 3.11 (-1.58%)
INKT : 10.87 (-0.64%)
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC

Noetik’s TARIO-2 platform analyzed routine pretreatment H&E images from 113 BOT+BAL-treated patients and identified spatial tumor microenvironment patterns associated with response and survival ...

AGEN : 3.11 (-1.58%)
INKT : 10.87 (-0.64%)
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer

Published prospective cohort showed durable responses and manageable safety in patients with HCC following prior immunotherapy Median overall survival of 12.3 months in a heavily pretreated...

AGEN : 3.11 (-1.58%)
INKT : 10.87 (-0.64%)
Agenus: Q1 Earnings Snapshot

Agenus: Q1 Earnings Snapshot

AGEN : 3.11 (-1.58%)
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development

Authorized access interest continues to expand across regions Phase 3 BATTMAN trial commenced patient enrollment in April 2026, advancing BOT+BAL into pivotal evaluation ...

AGEN : 3.11 (-1.58%)
INKT : 10.87 (-0.64%)
Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

Agenus Inc . (“Agenus”) (Nasdaq: AGEN ), a leader in immuno-oncology, today announced that the Company will release its first quarter 2026 financial results before...

AGEN : 3.11 (-1.58%)
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026

Four abstracts accepted across melanoma, colorectal cancer, and translational research

AGEN : 3.11 (-1.58%)
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

Partnership enables timely access to botensilimab plus balstilimab through France’s government-reimbursed Autorisation d’Accès Compassionnel (AAC) pathway and paid named-patient programs (NPP) in...

AGEN : 3.11 (-1.58%)
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer

First study combining botensilimab (BOT) and balstilimab (BAL) with agenT-797 in gastroesophageal cancer shows disease control rate (DCR) of 77% in patients and long-term survival beyond 20 months in a...

AGEN : 3.11 (-1.58%)
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

Study highlights novel multi-mechanistic immunotherapy combination in checkpoint-refractory disease Data expected to inform immune modulation, treatment sequencing, and durability of...

AGEN : 3.11 (-1.58%)

Business Summary

Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's...

See More

Key Turning Points

3rd Resistance Point 3.61
2nd Resistance Point 3.48
1st Resistance Point 3.30
Last Price 3.11
1st Support Level 2.99
2nd Support Level 2.86
3rd Support Level 2.68

See More

52-Week High 7.34
Fibonacci 61.8% 5.57
Fibonacci 50% 5.03
Fibonacci 38.2% 4.48
Last Price 3.11
52-Week Low 2.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.